Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences expecting sales boost from new co-marketing deal with ISS

The two companies think they can improve ISS’s high pressure optical cell system by combining it with PBIO’s automated pressure generators
pressure gauge
ISS currently uses an “archaic” hand cranking mechanism to control pressure in its devices, while PBIO’s technology allows pressure to be increased or decreased “like a light switch”

Pressure BioSciences Inc (OTCQB:PBIO) has signed a two-year worldwide co-marketing and distribution agreement with Illinois-based medical instruments maker ISS.

One of the products ISS makes is a spectrophotometer - an instrument used in drug discovery and development - the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As it name suggests, Pressure Bio manufactures automated pressure generators which can increase and decrease pressure “like a light switch”.

‘If you buy this, you should buy this too’

The two companies have been in talks for a little while about bringing their two systems together and after Wednesday's tie-up they will actively look to market each other’s devices.

“We are going to sell our customers that reach out to us and we will then let [the customers] know that they can talk directly to [ISS] about buying the spectrophotometer from them,” said PBIO President and chief executive Richard Schumacher in a conference call.

“If [ISS] gets requests coming in they will either shuttle them to us or sell the pressure cell and the spectrophotometer and then send [the customer details] to us to sell the pressure generating equipment.”

Pressure’s VP marketing and sales, Nate Lawrence, added: “The unique combination of PBI’s high pressure generators and ISS’s high pressure optical cell system is expected to greatly benefit scientists in academic institutions, industry and governments who study biological samples and processes at the molecular level.”

Tie-up should increase sales

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000-US$50,000 each.

The company don’t sell many of these units at the moment, Schumacher said, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

Pressure Bio and ISS will both be at the Biophysical Society in San Francisco this weekend, where both parties will talk about their new partnership.

Shares were flat at US$3.85 on Wednesday.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use